• It’s the news of the day and we were the SECOND site to report it: Dendreon’s Provenge met its primary endpoint. See our original post and our Twitter page for the details. Xconomy and the WSJ also had good takes. Some analysts, however, are still skeptical because the full data was not released and is embargoed until AUA. [Reuters UK]

• Evotec’s investigational drug for smoking cessation, a monoamine oxidase inhibitor, fails in a Phase 2 proof-of-concept study. Iguana is Ok with this given that that there’s dozens of drugs for this!! [Yahoo!Finance]

• FDA says no to Medicis’ Reloxin, a generic Botox. [Bloomberg]

• SpePharm is after BioAlliance for $46M, claims wrongfully terminated Loramyc license. [FierceBiotech]

• Amgen touts preclinical results of AMG-749, a fully human anti-IGF-1 monoclonal antibody that has demonstrated a reduction in pancreatic cancer cell growth. [Genetic Engineering & Biotechnology News]

• CEL-SCI sends letters to shareholders discussing Dendreon’s success, hopes to jump-start stock up from two dimes and nickel. Letter not so effective. [Yahoo!Finance]

• Finally, Johnson & Johnson’s first-quarter net income slipped 2.5% as a stronger dollar ate into foreign sales and Zyrtec went generic. [WSJ]

Image from cnbc

Related Posts